NCT05410535View on ClinicalTrials.gov

To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

PHASE4CompletedINTERVENTIONAL
Enrollment

431

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Gastric Cancer
Interventions
DRUG

Patients who continued UDCA 300mg medication

patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

OTHER

Patients who discontinued UDCA 300mg prescription

patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Trial Locations (1)

Unknown

DoJoong Park, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY